论文部分内容阅读
目的 探讨术前化疗对进展期 (Ⅲ、Ⅳ期 )小儿神经母细胞瘤血管形成状态的影响及其可能的作用机制和临床意义。方法 利用第Ⅷ因子相关抗原 (F8 RA)抗体 ,应用免疫组化法检测小儿神经母细胞瘤中的微血管计数。结果 15例进展期 (Ⅲ、Ⅳ期 )小儿神经母细胞瘤患儿中 ,术前化疗组 9例 ,平均微血管数为 2 5 .6 3。非术前化疗组 6例 ,平均微血管数为 39.0 0 ,明显高于术前化疗组(P <0 .0 5 ) ;术前化疗组患儿的平均生存时间为 86 2 .5d ,而非术前化疗组患儿的平均生存时间仅为372d ,明显少于术前化疗组 (P <0 .0 5 )。结论 进展期小儿神经母细胞瘤患儿的术前化疗可抑制其血管形成 ,改善预后。
Objective To investigate the effect of preoperative chemotherapy on the angiogenesis of advanced neuroblastoma in children (III, IV) and its possible mechanism and clinical significance. Methods VIII factor-associated antigen (F8 RA) antibody was used to detect the microvessel count in children with neuroblastoma by immunohistochemistry. Results Among the 15 children with advanced neuroblastoma in stage III and IV, 9 cases were preoperative chemotherapy group and the average number of microvessels was 25.63. In the non-preoperative chemotherapy group, the average number of microvessels was 39.0 0 , which was significantly higher than that of the preoperative chemotherapy group (P 0.05). The average survival time of the preoperative chemotherapy group was 86 2 5d, but not The average survival time of children in the pre-chemotherapy group was only 372 days, which was significantly less than the preoperative chemotherapy group (P < 0.05). Conclusion Preoperative chemotherapy for children with advanced neuroblastoma can inhibit their vascularization and improve their prognosis.